ClinicalTrials.gg

Mucopolysaccharidosis II clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 77 studies for Mucopolysaccharidosis II across more than 10 countries. 8 are recruiting or about to start. 51 of them are mainly about Mucopolysaccharidosis II (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09.

Status

Completed
40
Active, not recruiting
15
Terminated
9
Recruiting
4
Withdrawn
3
Enrolling by invitation
3

Phase

Phase 2
31
Phase 1
20
Phase 3
19
Phase 4
4

Where

United States
51
United Kingdom
21
Canada
13
Brazil
13
Spain
11
Germany
10

Who develops what

Add Mucopolysaccharidosis II to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 1 program from 1 company, 1 with this as their studies’ main aim; 0 with a live phase 3 study; 0 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
RituximabRecent, limited
Evidence
  • NCT05494593 · Takeda · Phase 4 · background · “Rituximab” · registered Aug 2022
Hoffmann-La Roche45% of its industry studiesUS: Hoffmann-La Roche (FDA 1997) + 3 othersEU: Hoffmann-La Roche (EMA 1998) + 6 others11 study
MethotrexateRecent, limited
Evidence
  • NCT05494593 · Takeda · Phase 4 · background · “Methotrexate” · registered Aug 2022
Hoffmann-La Roche28% of its industry studiesUS: off-patent, 21 generics marketedEU: Nordic Group B.V. (EMA 2016) + 1 other11 study
Immunoglobulins, IntravenousRecent, limited
Evidence
  • NCT05494593 · Takeda · Phase 4 · background · “Intravenous Immunoglobulin (IVIG)” · registered Aug 2022
Takeda22% of its industry studiesEU: Takeda (EMA 2006) + 2 others11 study

1 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 1 program — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Mucopolysaccharidosis II studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

9studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 9, phase 3 first

Who these studies take

Of the 4 Mucopolysaccharidosis II studies recruiting now, 1 (25%) set no upper age limit and 3 (75%) stop at 75 or younger. 4 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 4
AgeWomenMen
104 (100%)4 (100%)
184 (100%)4 (100%)
303 (75%)3 (75%)
403 (75%)3 (75%)
503 (75%)3 (75%)
651 (25%)1 (25%)
751 (25%)1 (25%)
851 (25%)1 (25%)

Across all 77 studies, recruiting or not: 61% stop at 75 or younger and 60% at 65; 92% take children; 0% are for women only and 52% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Mucopolysaccharidosis II studies take

Of 16 observational studies under Mucopolysaccharidosis II, half reached primary completion within 51 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Observational51 mo24–119 · 16 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 77. Browse all 77 → or search them.